Related Experiment Video

Updated: Oct 19, 2025

Real-time Analyses of Retinol Transport by the Membrane Receptor of Plasma Retinol Binding Protein
14:32

Real-time Analyses of Retinol Transport by the Membrane Receptor of Plasma Retinol Binding Protein

Published on: January 28, 2013

13.8K

Retinol binding protein 4 antagonists and protein synthesis inhibitors: Potential for therapeutic development

Noheul Kim1, Ronny Priefer1

  • 1Massachusetts College of Pharmacy and Health Sciences University, Boston, MA, USA.

European Journal of Medicinal Chemistry
|September 21, 2021
PubMed

Insights

Retinol-binding protein 4 (RBP4) is linked to various diseases. Developing RBP4 antagonists offers a promising therapeutic strategy for conditions like insulin resistance and cardiovascular disease.

Area of Science:

  • Biochemistry
  • Endocrinology
  • Pharmacology

Background:

  • Retinol-binding protein 4 (RBP4) is a key serum transporter for Vitamin A.
  • Elevated RBP4 levels are associated with metabolic syndromes, including insulin resistance, type 2 diabetes, cardiovascular diseases, obesity, and macular degeneration.

Purpose of the Study:

  • To review the therapeutic potential of targeting RBP4.
  • To highlight the development of RBP4 antagonists and protein synthesis inhibitors.

Main Methods:

  • Review of preclinical and clinical studies on RBP4 antagonists.
  • Analysis of existing data on drugs and nutraceuticals affecting RBP4 expression.

Main Results:

  • Several RBP4 antagonists, such as BPN-14136, have shown promising safety and efficacy in animal models.
  • Tinlarebant and STG-001 are RBP4 antagonists currently in clinical trials.
  • Some antidiabetic drugs and nutraceuticals may reduce RBP4 expression, but require further clinical validation.

Conclusions:

  • Targeting RBP4 presents a potential therapeutic avenue for a range of diseases.
  • Further research is crucial for developing clinically effective RBP4 antagonists or protein synthesis inhibitors.
Keywords:
Direct antagonistsFenretinideProtein synthesis inhibitorsRetinol-binding protein 4

More Related Videos

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions08:18

Author Spotlight: Unraveling Vitamin A Transport Mechanisms — Linking Liver Receptors to Vision Health Through RBPR2 and RBP4 Interactions

Published on: October 4, 2024

1.3K
Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling05:03

Author Spotlight: Investigating Physiological Functions of Vitamin A Transporters Using HPLC-Based Vitamin A Profiling

Published on: December 27, 2024

1.3K

Related Concept Videos

Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.1K
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
294
Transducer Mechanism: Nuclear Receptors01:31

Transducer Mechanism: Nuclear Receptors

Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.9K
Targets for Drug Action: Overview01:26

Targets for Drug Action: Overview

Drugs target macromolecules to modify ongoing cellular processes. Primary drug targets include receptors, ion channels, transporters, and enzymes.
Receptors are either membrane-spanning or intracellular proteins, which upon binding a ligand, get activated and transmit the signal downstream to elicit a response. Drugs bind receptors, either mimicking the action of endogenous ligands or blocking the receptor activity to bring about a modified response. Nearly 35% of approved drugs target the G...
8.2K
Eukaryotic Transcription Inhibitors01:52

Eukaryotic Transcription Inhibitors

Certain biochemical processes, such as embryonic development and cell growth regulation, depend on the repression of specific genes. DNA binding proteins known as eukaryotic transcription inhibitors regulate the repression of gene expression in eukaryotes. The presence of these inhibitors at the required location and time in the cell is triggered by the presence of hormones and additional signals from other cells.
Eukaryotic transcription inhibitors usually contain two distinct domains, a...
10.1K
Factors Affecting Protein-Drug Binding: Drug Interactions01:23

Factors Affecting Protein-Drug Binding: Drug Interactions

Drug interactions are a critical aspect of pharmacology and can occur when two or more drugs compete for the same binding site. This competition can result in one drug displacing another, altering the effect of the displaced drug. Drug interactions are complex processes that rely heavily on how much of the displacer drug is present and how strongly it can bind to the same sites as the displaced drug.
Displacement interactions can have varying outcomes, ranging from toxicity to virtually...
348